Weight-loss drugs are poised to revolutionise healthcare by slowing down the ageing process and by allowing people to live for longer and in better health. That is the dramatic message from leading scientists after studies were presented last week at the European Society of Cardiology Conference in London.
Research has already found that semaglutide – also known by the brand names Wegovy and Ozempic – reduced the risk of death in people who were obese or overweight and had cardiovascular disease.
